【美国V视讯】美东时间 2025 年 12 月 16 日，专注于 AI-HIFU（高强度聚焦超声）无创治疗技术的医疗科技平台 Sonablate 举办的“圣诞臻享夜”在纽约 POSX 喜宴大酒楼隆重举行。活动邀请了 100 余位商界人士、医学专家、产业研究者及长期关注医疗科技发展的专业人士，围绕前列腺疾病治疗的临床现实、技术演进、真实世界数据以及可持续产业化路径，展开了一场理性、克制、以长期价值为导向的深度交流。

New York (Eastern Time), December 16, 2025 — Sonablate, a medical technology platform dedicated to AI-HIFU (High-Intensity Focused Ultrasound) non-invasive therapeutic solutions, successfully hosted its “Christmas Private Evening” in New York at POSX Banquet Hall. The event brought together more than 100 business leaders, medical experts, industry researchers, and professionals who have long followed the development of medical technology. Discussions focused on the clinical realities of prostate disease treatment, technological evolution, real-world data, and sustainable pathways for industrialization, fostering a rational and long-term value-oriented dialogue.

活动伊始，Sonablate Corp. 首席执行官 Richard Yang 发表主题发言，系统阐述了 AI-HIFU 在真实世界中的应用路径。他指出，不同于仍停留在概念验证或单点技术阶段的方案，AI-HIFU 已逐步形成一套完整、可落地的治疗逻辑，涵盖精准肿瘤控制、器官功能保留、微创乃至无创操作模式以及较短的术后恢复周期，并能够与现有主流治疗体系实现兼容与重复应用。

At the opening of the event, Richard Yang, Chief Executive Officer of Sonablate Corp., delivered a keynote presentation outlining the real-world application pathway of AI-HIFU. He emphasized that, unlike solutions still confined to conceptual validation or single-point technologies, AI-HIFU has evolved into a comprehensive and clinically deployable therapeutic logic. This framework integrates precise tumor control, organ preservation, minimally invasive and even non-invasive procedures, as well as shortened recovery cycles, while remaining compatible with existing standard-of-care treatment systems and allowing for repeat use when clinically appropriate.

据介绍，该技术已历经 18 年临床应用验证，在全球范围内累计治疗 70,000 余名真实患者，并获得 200 余篇医学文献支持。上述真实世界数据表明，该技术所面临的核心问题，已不再是“是否可行”，而是“如何在既有医疗体系中被持续、规范、规模化地应用”。

According to Sonablate, the technology has undergone 18 years of clinical application and validation, with more than 70,000 real-world patients treated globally and support from over 200 peer-reviewed medical publications. These real-world data demonstrate that the core question facing AI-HIFU is no longer whether the technology is feasible, but rather how it can be continuously, systematically, and at scale integrated into existing healthcare systems.

作为全球无创医疗领域的奠基人物之一，黄教悌 教授从医学发展史与前列腺癌整体治疗格局出发，系统梳理了当前临床实践中面临的核心矛盾。他指出，前列腺癌是男性最常见的恶性肿瘤之一，美国男性终身患病风险约为 1/8。尽管过去十年中发病率持续上升、死亡率有所下降，但下降速度已明显放缓，前列腺癌仍是北美男性第二大致死癌症。

Professor Jiao-Ti Huang, one of the pioneers of non-invasive medical therapy worldwide, provided a historical and clinical perspective on the evolving prostate cancer treatment landscape. He noted that prostate cancer remains one of the most common malignancies among men, with a lifetime risk of approximately 1 in 8 for U.S. males. Although incidence rates have continued to rise over the past decade and mortality rates have declined, the pace of mortality reduction has slowed significantly. Prostate cancer remains the second leading cause of cancer-related death among men in North America.

在现实医疗选择中，患者长期处于两个极端之间：一端是“观察等待”，另一端则是可能带来尿失禁、性功能障碍及长期生活质量影响的根治性治疗。医学发展的长期趋势始终清晰而一致——从有创，到微创，再到无创。真正的医学进步，并不在于治疗手段的激进化，而在于在确保疗效的前提下，持续降低对人体本身的损伤。Sonablate AI-Robotic HIFU 正是在这一趋势下，提供了兼具良好疾病控制与术后高品质生活质量的“两全其美”的治疗方式。

In real-world clinical decision-making, patients are often caught between two extremes: “active surveillance” on one end and radical treatments on the other, which may lead to urinary incontinence, sexual dysfunction, and long-term quality-of-life impairment. The long-term trajectory of medicine is clear and consistent—from invasive, to minimally invasive, and ultimately to non-invasive approaches. True medical progress lies not in increasing therapeutic aggressiveness, but in achieving effective disease control while continuously reducing harm to the human body. In this context, Sonablate’s AI-Robotic HIFU offers a balanced solution that delivers strong disease control while preserving post-treatment quality of life.

林氏集团主席 林建中 及多位与会嘉宾也从真实人生经验出发分享了他们的判断：当疾病真正发生在家人身上时，所有复杂模型和技术参数都会迅速退居其次，决策标准最终回归到最本质的问题——是否安全、是否温和、是否值得推荐给身边最重要的人。在充分理解技术成熟度、临床安全性及长期发展路径之后，他们选择持续关注并支持无创治疗方向。这类判断既建立在理性分析之上，也经得起现实生活的长期检验。

Mr. John Lam, Prosident of Lam Group, along with several other attendees, shared perspectives grounded in real-life experience. They emphasized that when illness affects one’s own family members, complex models and technical parameters quickly fade into the background, and decision-making returns to fundamental questions: Is it safe? Is it gentle? Would I recommend it to the people I care about most? After gaining a thorough understanding of the technology’s maturity, clinical safety, and long-term development pathway, they expressed continued confidence in and support for non-invasive treatment approaches. Such judgments, they noted, are grounded in rational analysis and validated by real-life experience.

随后，Sonablate 战略与投资部负责人 Peter 陈先生 代表公司对各界嘉宾的到来与长期支持表示感谢。他指出，许多真正改变行业格局的技术，在早期阶段往往并不“显眼”。它们最终获得成功，并非依赖短期速度或市场情绪，而是因为顺应了医学发展的必然方向，并在真实世界中不断打磨、验证与完善。当一项技术在医学方向、真实世界数据与合规路径之间形成闭环，其长期价值判断便具备了坚实基础。

Peter Chen, Head of Strategy and Investment at Sonablate, expressed gratitude on behalf of the company for the presence and long-standing support of attendees. He noted that many technologies that ultimately reshape industries are not highly visible in their early stages. Their success is rarely driven by short-term momentum or market sentiment, but rather by alignment with the fundamental direction of medical progress and continuous refinement through real-world application and validation. When a technology forms a closed loop among clinical direction, real-world data, and regulatory and compliance pathways, its long-term value proposition becomes well substantiated.

他表示，对于长期关注医疗科技、无创治疗以及医疗体系效率提升的专业人士而言，这类已经完成核心技术验证、仍处于认知深化阶段的项目，值得被持续研究与理性讨论。看懂趋势、理解技术迭代逻辑的长期投资者，往往能够成为真正的长期价值受益者，正如早期理解并长期持有 NVIDIA、达芬奇手术机器人、Apple 和 Amazon 的投资者一样。

He further stated that for professionals who focus on medical technology innovation, non-invasive therapies, and healthcare system efficiency, projects that have already completed core technical validation yet remain in a phase of broader recognition and understanding merit ongoing research and rational discussion. Investors who understand long-term trends and technological iteration cycles are often those who ultimately benefit from enduring value creation—similar to early investors who recognized the potential of NVIDIA, the da Vinci Surgical System, Apple, and Amazon.

Sonablate 是一家专注于 AI-HIFU 无创治疗技术的医疗科技平台，致力于通过精准、非侵入式的治疗方式，在前列腺疾病等领域为患者提供兼顾疗效与生活质量的解决方案。公司长期聚焦于临床安全性、真实世界数据积累以及可持续产业化发展路径。

Sonablate is a medical technology platform dedicated to AI-HIFU non-invasive therapy, committed to providing solutions that balance therapeutic efficacy and quality of life in areas such as prostate disease. The company maintains a long-term focus on clinical safety, accumulation of real-world data, and sustainable industrialization.

此外，Sonablate 正在被系统性打造为一项平台型技术。其应用领域并不限于泌尿系统疾病，未来还将广泛覆盖除肺部疾病之外的各类软组织良性与恶性肿瘤治疗，并进一步延伸至干细胞治疗、CAR-T 细胞相关医学应用以及医美领域，致力于推动无创、精准、以生活质量为核心的治疗模式成为全球医学的新方向，引领世界无创局灶治疗的新时代。

In addition, Sonablate is being systematically developed as a platform technology. Its applications are not limited to urology but are expected to extend broadly to the treatment of benign and malignant soft-tissue tumors across multiple organ systems—excluding pulmonary diseases—as well as to stem cell therapy, CAR-T cell–related medical applications, and aesthetic medicine. Through these efforts, Sonablate aims to advance non-invasive, precision, quality-of-life-centered treatment paradigms as a new global medical standard, ushering in a new era of non-invasive focal therapy worldwide.